Evidence map›Paper›PMID 35531123›Full record

ArticleCanadian journal of gastroenterology & hepatology2022

Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study.

Wencong Li, Jing Liang, Jihong An, Lingdi Liu, Yihui Hou, Lu Li, Wen Zhao, Luyao Cui, Ningning Xue, Zaid Al-Dhamin and 3 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Wencong LiDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0001-6061-4205
Jing LiangDepartment of Hepatology, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China.ORCID 0000-0001-5114-9030
Jihong AnDepartment of Infectious Diseases, Inner Mongolia People's Hospital, Hohhot 010017, China.ORCID 0000-0002-8766-244X
Lingdi LiuDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0003-4286-5603
Yihui HouDepartment of Infectious Diseases, The First Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China.ORCID 0000-0003-2014-2930
Lu LiDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0003-1078-9730
Wen ZhaoDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0001-5342-6724
Luyao CuiDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0002-9012-866X
Ningning XueDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0003-1620-4932
Zaid Al-DhaminDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0002-0503-2592
Tao HanDepartment of Hepatology, Tianjin Third Central Hospital, The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China.ORCID 0000-0003-4216-6968
Yuemin NanDepartment of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, China.ORCID 0000-0003-4192-099X
Liaoyun ZhangDepartment of Infectious Diseases, The First Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, China.ORCID 0000-0002-7666-7368
Hebei Medical University · CNShanxi Medical University · CNTianjin Third Central Hospital · CNInner Mongolia People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods: The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results: Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, Conclusions: Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.

Indexed as

Antiviral AgentsHepatitis C, ChronicDrug Therapy, CombinationGenotypeHepacivirusHumansRibavirinSofosbuvirSustained Virologic ResponseTreatment OutcomeAntiviral AgentsRibavirinSofosbuvir

Identifiers

PMID35531123
PMCPMC9076341
OpenAlexW4225150678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.